GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Prostatype Genomics AB (OSTO:PROGEN) » Definitions » PS Ratio

Prostatype Genomics AB (OSTO:PROGEN) PS Ratio : 8.25 (As of May. 19, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Prostatype Genomics AB PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Prostatype Genomics AB's share price is kr0.066. Prostatype Genomics AB's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was kr0.01. Hence, Prostatype Genomics AB's PS Ratio for today is 8.25.

The historical rank and industry rank for Prostatype Genomics AB's PS Ratio or its related term are showing as below:

OSTO:PROGEN' s PS Ratio Range Over the Past 10 Years
Min: 4.1   Med: 33.15   Max: 496.65
Current: 8.25

During the past 5 years, Prostatype Genomics AB's highest PS Ratio was 496.65. The lowest was 4.10. And the median was 33.15.

OSTO:PROGEN's PS Ratio is ranked worse than
78.9% of 218 companies
in the Medical Diagnostics & Research industry
Industry Median: 3.015 vs OSTO:PROGEN: 8.25

Prostatype Genomics AB's Revenue per Sharefor the three months ended in Jun. 2023 was kr0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was kr0.01.

During the past 12 months, the average Revenue per Share Growth Rate of Prostatype Genomics AB was -55.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was 104.10% per year.

During the past 5 years, Prostatype Genomics AB's highest 3-Year average Revenue per Share Growth Rate was 111.80% per year. The lowest was 104.10% per year. And the median was 107.95% per year.

Back to Basics: PS Ratio


Prostatype Genomics AB PS Ratio Historical Data

The historical data trend for Prostatype Genomics AB's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prostatype Genomics AB PS Ratio Chart

Prostatype Genomics AB Annual Data
Trend Jun18 Jun19 Dec21 Dec22 Dec23
PS Ratio
- - - 11.97 5.59

Prostatype Genomics AB Quarterly Data
Jun18 Jun19 Mar20 Jun20 Sep20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 92.25 11.97 12.79 30.16 -

Competitive Comparison of Prostatype Genomics AB's PS Ratio

For the Diagnostics & Research subindustry, Prostatype Genomics AB's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Prostatype Genomics AB's PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Prostatype Genomics AB's PS Ratio distribution charts can be found below:

* The bar in red indicates where Prostatype Genomics AB's PS Ratio falls into.



Prostatype Genomics AB PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Prostatype Genomics AB's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=0.066/0.008
=8.25

Prostatype Genomics AB's Share Price of today is kr0.066.
Prostatype Genomics AB's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.01.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Prostatype Genomics AB  (OSTO:PROGEN) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Prostatype Genomics AB PS Ratio Related Terms

Thank you for viewing the detailed overview of Prostatype Genomics AB's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Prostatype Genomics AB (OSTO:PROGEN) Business Description

Traded in Other Exchanges
Address
Gustaf III:s Boulevard 34, Solna, SWE, 169 73
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.

Prostatype Genomics AB (OSTO:PROGEN) Headlines

No Headlines